Literature DB >> 19146907

BAFF enhances B-cell-mediated immune response and vaccine-protection against a very virulent IBDV in chickens.

Long Chen1, Mao Ju Ran, Xiao Xiao Shan, Meng Cao, Peng Cao, Xiao Man Yang, Shuang Quan Zhang.   

Abstract

Infectious bursal disease (IBD) is an acute, highly infectious and immunosuppressive disease caused by IBDV, which specifically targets destruction of B cells in the bursa of Fabricius. B-cell activating factor belonging to the TNF family (BAFF, also called BLyS, TALL-1, THANK, or zTNF4) is an important factor for B-cell proliferation and survival. Here we demonstrate that human soluble BAFF (hsBAFF) may enhance humoral immune response by elevating B lymphocyte activity of secretion of immunoglobulin (Ig) such as IgA, IgM and IgG in chickens immunized or unimmunized with an inactivated IBDV vaccine from a very virulent strain. Of importance, we found that hsBAFF, as a co-immunostimulant for vaccination, may play a vital role in amplifying the specific protective immune response, thereby potently preventing very virulent IBDV challenge. This is supported by serological evidence that hsBAFF may effectively enhance higher specific IgG activity and titre in serum of immunized chickens. The findings strongly suggest that BAFF may be exploited in combination with specific vaccination for prevention of IBD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146907     DOI: 10.1016/j.vaccine.2008.12.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 2.  The Role of BAFF System Molecules in Host Response to Pathogens.

Authors:  Jiro Sakai; Mustafa Akkoyunlu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

3.  Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

Authors:  J Westra; S van Assen; K R Wilting; J Land; G Horst; A de Haan; M Bijl
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

4.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

5.  Effects of B cell-activating factor on tumor immunity.

Authors:  Mark Yarchoan; Won Jin Ho; Aditya Mohan; Yajas Shah; Teena Vithayathil; James Leatherman; Lauren Dennison; Neeha Zaidi; Sudipto Ganguly; Skylar Woolman; Kayla Cruz; Todd D Armstrong; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2020-05-21

6.  Transcriptome Analysis and Identification of Differentially Expressed Transcripts of Immune-Related Genes in Spleen of Gosling and Adult Goose.

Authors:  Anqi Wang; Fei Liu; Shun Chen; Mingshu Wang; Renyong Jia; Dekang Zhu; Mafeng Liu; Kunfeng Sun; Ying Wu; Xiaoyue Chen; Anchun Cheng
Journal:  Int J Mol Sci       Date:  2015-09-22       Impact factor: 5.923

7.  Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responses.

Authors:  Joseph R Plummer; James P McGettigan
Journal:  PLoS Negl Trop Dis       Date:  2019-11-14

Review 8.  Considerations for Novel COVID-19 Mucosal Vaccine Development.

Authors:  Wael Alturaiki
Journal:  Vaccines (Basel)       Date:  2022-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.